Bellerophon Therapeutics, Inc. announced top-line results from Cohort 1 of the Company’s ongoing Phase 2b randomized, double-blind, placebo-controlled clinical study (iNO-PF) evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). Statistically significant improvements in multiple clinically meaningful activity parameters as measured by a wearable medical-grade activity monitor (actigraphy) were observed: Subjects on pulsed inhaled nitric oxide (iNO) demonstrated an increase of 8% in moderate activity versus a 26% decrease for subjects on placebo (p=0.04) Subjects on iNO showed no decline in their overall activity levels versus a 12% decline for subjects on placebo (p=0.05) Wearable activity monitoring is designed to provide continuous objective real-world physical activity data and is scientifically validated to assess patient outcomes. Actigraphy is currently being utilized as the primary endpoint in multiple late-stage clinical programs in pulmonary hypertension and other cardiopulmonary diseases. Clinically meaningful improvements were also demonstrated in the following key areas: Subjects on iNO showed an increase of 15% in NT-ProBNP versus a 42% increase for subjects on placebo. NT-ProBNP is a peptide marker of right ventricular failure, with higher levels indicative of disease worsening. Subjects on iNO demonstrated improved oxygen saturation by 9% versus a worsening of 11% for placebo. In addition, iNO was well-tolerated with no safety concerns.